Research on
Lodonal for HIV related
GI complications featured in Plus Magazine
Orlando, FL --
July 19, 2018 -- InvestorsHub NewsWire -- Immune Therapeutics, Inc.
(OTCQB:IMUN)
("Immune" "IMUN" or the "Company"), a clinical late stage
biopharmaceutical company focused on the development of therapies
for the treatment of autoimmune diseases, inflammatory diseases,
cancer and HIV/AIDS announced today that their lead therapy,
Lodonal (LDN), was
featured in an article published in Plus Magazine[dm1]:
https://www.hivplusmag.com/i-am-warrior/2018/7/12/will-needs-long-term-survivors-be-heard.
Plus Magazine
(formally HIVPlus Magazine) was founded in 1998 and
is a leading direct to consumer
publication providing cutting edge information on HIV research,
treatment, prevention and policy. Plus Magazine is distributed in
the waiting rooms of AIDS service organization, HIV clinics and HIV
specialists across the United States.
"The incidence
of GI complication in HIV
patients is on the rise exponential to increasing survival rates
but still remain unaddressed and contributing to treatment
failures and costs of long
term management of HIV," stated Noreen Griffin, Immune Therapeutics CEO.
"The publication
in HIV Plus is raising awareness of this clinical disparity that
will provoke dialogue at AIDS 2018[dm2] on the
clinical options, including Lodonal for treating Crohn's IBS , IBD, UC and C.DIF in studies being considered
by investigators in recognized publically supported clinical research networks[dm3]."
The
article, Will The
Needs of Long-Term Survivors Be Heard,
published in the July edition of Plus, outlines the need for a concentrated focus
by HIV medical and
research communities to address the issues of accelerated aging and
HIV GI co- morbidities including Crohn's disease, UC and IBS. HIV co- morbidities are
now the leading cause of death among HIV patients. The article
suggests that data on LDN strongly supports further studies in HIV
by the AIDS Clinical Trials Groups (ACTG's), a federally funded HIV
clinical trials system supported by the National
Institute of Allergies and Infectious Diseases
(NIAID). Will The
Needs of Long-Term Survivors Be Heard sites the study of LDN in Crohn's patients as well as the data from studies of
LDN in HIV patients. The article also mentions an ongoing study
(PETERPAIN[dm4]), which
is studying pain in HIV
patients. The study, which takes place at Boston Medical
Center, is analyzing the
effect of low- dose
naltrexone, similar to that of LDN, and a second opioid receptor
antagonist,
Nalmefene on pain.
ABOUT IMMUNE THERAPEUTICS,
INC.
Immune
Therapeutics Inc. is a late stage clinical stage biopharmaceutical
company focused on the development and commercialization of our
highly innovative immunotherapies. IMUN is a biotechnology company
developing T-Activation immunotherapies to achieve immunomodulation
in patients with autoimmune and inflammatory disease and cancer and
infectious diseases.
Stimulating the
body's immune system remains one of the most promising approaches
in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory
conditions and other chronic infectious diseases.
Forward-Looking
Statements
This release may
contain forward-looking statements. Actual results may differ from those
projected due
to a number of risks and
uncertainties, including, but not limited to, the possibility that
some or all the matters and transactions considered by the Company
may not proceed as contemplated, and by all other matters specified in the
Company's filings with the Securities and Exchange
Commission.
These statements are made based
upon current expectations that are subject to risk and
uncertainty.
The Company does not undertake to
update forward-looking statements in this news release to reflect
actual results, changes in assumptions or changes in other factors
affecting such forward-looking information. Assumptions and other information that could
cause results to differ from those set forth in the forward-looking
information can be found in the Company's filings with the
Securities and Exchange Commission (www.sec.gov), including its
recent periodic reports.
888-613-8802
http://www.immunetherapeutics.com/
http://www.immunetherapeutics.com/